Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3060% above fair value
$7.10+0.05 (+0.71%)
Close on Nov 18, 2026Market cap $195.97MP/E –Yield –
Precision BioSciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Precision BioSciences's revenue for the twelve months ending Jun 30, 2026 was $45.06M, up 3473.0% year over year. For fiscal 2025 it was $34.26M, down 50.1% from the year before. The highest annual figure on record is $115.53M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.26M | -50.1% |
| FY2024 | Dec 31, 2024 | $68.70M | +41.0% |
| FY2023 | Dec 31, 2023 | $48.73M | +94.1% |
| FY2022 | Dec 31, 2022 | $25.10M | -78.3% |
| FY2021 | Dec 31, 2021 | $115.53M | +375.7% |
| FY2020 | Dec 31, 2020 | $24.29M | +9.2% |
| FY2019 | Dec 31, 2019 | $22.24M | +104.3% |
| FY2018 | Dec 31, 2018 | $10.88M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $10.84M | +37272.4% |
| Q4 FY2025 | Dec 31, 2025 | $34.20M | +5261.1% |
| Q3 FY2025 | Sep 30, 2025 | $13.00K | -97.7% |
| Q2 FY2025 | Jun 30, 2025 | $18.00K | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $29.00K | -99.8% |
| Q4 FY2024 | Dec 31, 2024 | $638.00K | -90.9% |
| Q3 FY2024 | Sep 30, 2024 | $576.00K | -95.6% |
| Q2 FY2024 | Jun 30, 2024 | $49.90M | +152.2% |
| Q1 FY2024 | Mar 31, 2024 | $17.58M | +100.3% |
| Q4 FY2023 | Dec 31, 2023 | $7.04M | -33.6% |
| Q3 FY2023 | Sep 30, 2023 | $13.12M | +78.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.79M | +418.0% |
| Q1 FY2023 | Mar 31, 2023 | $8.78M | +164.7% |
| Q4 FY2022 | Dec 31, 2022 | $10.60M | +67.2% |
| Q3 FY2022 | Sep 30, 2022 | $7.36M | -69.4% |
| Q2 FY2022 | Jun 30, 2022 | $3.82M | -94.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.32M | -79.7% |
| Q4 FY2021 | Dec 31, 2021 | $6.34M | -28.3% |
| Q3 FY2021 | Sep 30, 2021 | $24.04M | +226.4% |
| Q2 FY2021 | Jun 30, 2021 | $68.81M | +6282.7% |
| Q1 FY2021 | Mar 31, 2021 | $16.35M | +133.6% |
| Q4 FY2020 | Dec 31, 2020 | $8.85M | +35.6% |
| Q3 FY2020 | Sep 30, 2020 | $7.36M | +51.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.08M | -80.0% |
| Q1 FY2020 | Mar 31, 2020 | $7.00M | +28.1% |
| Q4 FY2019 | Dec 31, 2019 | $6.52M | +32.0% |
| Q3 FY2019 | Sep 30, 2019 | $4.87M | +91.5% |
| Q2 FY2019 | Jun 30, 2019 | $5.39M | +187.6% |
| Q1 FY2019 | Mar 31, 2019 | $5.46M | +257.5% |
| Q4 FY2018 | Dec 31, 2018 | $4.94M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.54M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.87M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.53M | – |
See a number that looks wrong?